Drawing for UNLOCK I-O

USPTO serial 88435764

UNLOCK I-O

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
BATT, JAIME L
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with UNLOCK I-O?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Caroline H. Mead

Caroline H. Mead SQUIRE PATTON BOGGS (US) LLP275 BATTERY STREET, SUITE 2600SAN FRANCISCO, CA 94111UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals for the treatment of cancer and tumors; oncological pharmaceuticals; immuno-oncological pharmaceuticalsACTIVE—
009Downloadable electronic publications in the nature of booklets, workbooks, guides, pamphlets or brochures in the field of cancer, oncology, immuno-oncology and immuno-oncological pharmaceuticalsACTIVE—
016Printed educational materials in the field of cancer, oncology, immuno-oncology and immuno-oncological pharmaceuticalsACTIVE—
041Educational services, namely, informal on-line programs and printable materials distributed therewith in the field of cancer, oncology, and immuno-oncology and immuno-oncological pharmaceuticalsACTIVE—
042Pharmaceutical and immuno-oncological research and development; research and development of pharmaceuticals for the treatment of cancer and tumors; research and development in the field of oncology and immuno-oncologyACTIVE—
044Medical information; providing a web site featuring medical information; providing medical information in the field of cancer, oncology, immuno-oncology and immuno-oncological pharmaceuticalsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Dec 13, 2021MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 13, 2021ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 11, 2021NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 16, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 16, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 24, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 10, 2021PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 10, 2021ALIEASSIGNED TO LIE—
Feb 3, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 3, 2021ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Feb 3, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 28, 2021RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jun 12, 2020RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jun 2, 2020ALIEASSIGNED TO LIE—
Nov 11, 2019GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Nov 11, 2019GNSLLETTER OF SUSPENSION E-MAILED—
Nov 11, 2019CNSLSUSPENSION LETTER WRITTEN—
Nov 5, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 4, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 4, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 25, 2019DOCKASSIGNED TO EXAMINER—
Jun 19, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 19, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 19, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 8, 2019DOCKASSIGNED TO EXAMINER—
Jun 5, 2019MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jun 4, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 21, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance